Celularity Inc., a clinical-stage biotechnology company developing cell therapies and biomaterial products derived from the postpartum human placenta to treat cancer, infectious, and degenerative diseases, and Arthrex, Inc., a global leader in minimally invasive orthopedic technology, announced on July 1, 2021, that the companies have entered into an exclusive partnership to distribute and commercialize Celularity’s biomaterial products for orthopedic surgery and sports medicine.
Under the terms of the agreement, Celularity will provide Arthrex with exclusive commercial distribution rights for orthopedic surgery and sports medicine and will continue to be responsible for product manufacturing and supply.
